blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1305007

EP1305007 - PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS [Right-click to bookmark this link]
StatusOpposition procedure closed
Status updated on  22.02.2013
Database last updated on 24.08.2024
Most recent event   Tooltip27.09.2013Lapse of the patent in a contracting state
New state(s): TR		published on 30.10.2013  [2013/44]
Applicant(s)For all designated states
Bend Research, Inc.
64550 Research Road
Bend, OR 97701-8599 / US
[2011/13]
Former [2010/32]For all designated states
Bend Research, Inc
64550 Research Road
Bend OR 97701-8599 / US
Former [2003/18]For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, Connecticut 06340 / US
Inventor(s)01 / CURATOLO, William, John
Pfizer Global Research and Development, Eastern Point Road
Groton, CT 06340 / US
02 / FRIESEN, Dwayne, Thomas
60779 Currant Way
Bend, OR 97702 / US
03 / GUMKOWSKI, Michael, Jon
Pfizer Global Research and Development Eastern Point Road
Groton, CT 06340 / US
04 / LORENZ, Douglas, Alan
61332 King Jehu Way
Bend, OR 97702 / US
05 / NIGHTINGALE, James, Alan, Schriver
62900 Santa Cruz Avenue
Bend, OR 97701 / US
06 / RUGGERI, Roger, Benjamin
Pfizer Global Research and Development Eastern Point Road
Groton, CT 06340 / US
07 / SHANKER, Ravi, Mysore
Pfizer Global Research and Development Eastern Point Road
Groton, CT 06340 / US
 [2011/13]
Former [2003/18]01 / CURATOLO, William, John
Pfizer Global Resch and Devlpt, Eastern Point Rd
Groton, CT 06340 / US
02 / FRIESEN, Dwayne, Thomas
60779 Currant Way
Bend, OR 97702 / US
03 / GUMKOWSKI, Michael, Jon, Pfizer Resch and Develop
Eastern Point Road
Groton, CT 06340 / US
04 / LORENZ, Douglas, Alan
61332 King Jehu Way
Bend, OR 97702 / US
05 / NIGHTINGALE, James, Alan, Schriver
62900 Santa Cruz Avenue
Bend, OR 97701 / US
06 / RUGGERI, Roger, Benjamin, Pfizer Research & Develp
Eastern Point Road
Groton, CT 06340 / US
07 / SHANKER, Ravi, Mysore, Pfizer Resch and Develop.
Eastern Point Road
Groton, CT 06340 / US
Representative(s)Albrecht, Thomas, et al
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[N/P]
Former [2010/32]Albrecht, Thomas, et al
Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15
80539 München / DE
Former [2009/28]Wilson Gunn
Charles House 148/9 Great Charles Street
Birmingham B3 3HT / GB
Former [2009/13]Hill, Richard
Wilson Gunn Charles House 148/9 Great Charles Street
Birmingham B3 3HT / GB
Former [2003/18]Walls, Alan James
Pfizer Limited, UK Patent Department, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date01984472.931.07.2001
[2003/18]
WO2001IB01391
Priority number, dateUS20000223279P03.08.2000         Original published format: US 223279 P
[2003/18]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0211710
Date:14.02.2002
Language:EN
[2002/07]
Type: A2 Application without search report 
No.:EP1305007
Date:02.05.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 14.02.2002 takes the place of the publication of the European patent application.
[2003/18]
Type: B1 Patent specification 
No.:EP1305007
Date:30.03.2011
Language:EN
[2011/13]
Search report(s)International search report - published on:EP02.05.2002
ClassificationIPC:A61K9/14, A61K9/16
[2003/18]
CPC:
A61K9/1652 (EP,US); A61K31/47 (EP,KR,US); A61K31/4196 (EP,US);
A61K9/1635 (EP,US); A61P3/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P31/04 (EP);
A61P43/00 (EP); A61P7/00 (EP); A61P7/02 (EP);
A61P7/04 (EP); A61P9/00 (EP); A61P9/10 (EP);
A61P9/12 (EP); A61K9/146 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2003/18]
Extension statesAL23.01.2003
LT23.01.2003
LV23.01.2003
MK23.01.2003
RO23.01.2003
SI23.01.2003
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOREN[2003/18]
English:PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS[2003/18]
French:COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS DE PROTEINE DE TRANSFERT D'ESTER DE CHOLESTERYLE[2003/18]
Entry into regional phase23.01.2003National basic fee paid 
23.01.2003Designation fee(s) paid 
23.01.2003Examination fee paid 
Examination procedure02.11.2001Request for preliminary examination filed
International Preliminary Examining Authority: EP
23.01.2003Examination requested  [2003/18]
16.04.2008Despatch of a communication from the examining division (Time limit: M06)
21.10.2008Reply to a communication from the examining division
08.12.2008Despatch of a communication from the examining division (Time limit: M06)
05.06.2009Reply to a communication from the examining division
22.03.2010Communication of intention to grant the patent
22.07.2010Fee for grant paid
22.07.2010Fee for publishing/printing paid
Divisional application(s)EP10180614.9  / EP2258352
Opposition(s)Opponent(s)01  23.12.2011  10.08.2012  WITHDRAWN
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Hussain, Deeba
Merck Sharp & Dohme (UK) Limited
120 Moorgate
London EC2M 6UR / GB
 [N/P]
Former [2012/39]
Opponent(s)01  23.12.2011  10.08.2012  WITHDRAWN
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Hussain, Deeba
Merck Sharp & Dohme Limited Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Former [2012/06]
Opponent(s)01  23.12.2011   
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Opponent's representative
Hussain, Deeba
Merck Sharp & Dohme Limited Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
15.02.2012Invitation to proprietor to file observations on the notice of opposition
13.08.2012Reply of patent proprietor to notice(s) of opposition
07.11.2012Despatch of communication that the opposition procedure will be closed
17.11.2012Legal effect of closure of opposition procedure [2013/13]
Fees paidRenewal fee
05.09.2003Renewal fee patent year 03
20.09.2004Renewal fee patent year 04
01.08.2005Renewal fee patent year 05
31.07.2006Renewal fee patent year 06
31.07.2007Renewal fee patent year 07
31.07.2008Renewal fee patent year 08
28.07.2009Renewal fee patent year 09
26.07.2010Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
31.07.200303   M06   Fee paid on   05.09.2003
31.07.200404   M06   Fee paid on   20.09.2004
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT30.03.2011
BE30.03.2011
CY30.03.2011
DK30.03.2011
FI30.03.2011
IT30.03.2011
NL30.03.2011
SE30.03.2011
TR30.03.2011
GR01.07.2011
ES11.07.2011
CH31.07.2011
LI31.07.2011
LU31.07.2011
MC31.07.2011
PT01.08.2011
[2013/44]
Former [2013/25]AT30.03.2011
BE30.03.2011
CY30.03.2011
DK30.03.2011
FI30.03.2011
IT30.03.2011
NL30.03.2011
SE30.03.2011
GR01.07.2011
ES11.07.2011
CH31.07.2011
LI31.07.2011
LU31.07.2011
MC31.07.2011
PT01.08.2011
Former [2012/02]AT30.03.2011
BE30.03.2011
CY30.03.2011
FI30.03.2011
NL30.03.2011
SE30.03.2011
GR01.07.2011
ES11.07.2011
PT01.08.2011
Former [2011/51]AT30.03.2011
BE30.03.2011
CY30.03.2011
FI30.03.2011
SE30.03.2011
GR01.07.2011
ES11.07.2011
PT01.08.2011
Former [2011/47]AT30.03.2011
BE30.03.2011
CY30.03.2011
FI30.03.2011
SE30.03.2011
GR01.07.2011
PT01.08.2011
Former [2011/41]AT30.03.2011
BE30.03.2011
CY30.03.2011
FI30.03.2011
SE30.03.2011
GR01.07.2011
Former [2011/40]AT30.03.2011
CY30.03.2011
FI30.03.2011
SE30.03.2011
GR01.07.2011
Former [2011/37]CY30.03.2011
FI30.03.2011
SE30.03.2011
GR01.07.2011
Former [2011/36]SE30.03.2011
GR01.07.2011
Cited inInternational search[X]WO0017164  (PFIZER PROD INC [US], et al) [X] 1-15,17-20 * claims 1-5 * * page 77; example 3 *;
 [X]EP0992496  (PFIZER PROD INC [US]) [X] 1,13-15,18-20 * page 2, line 5 - line 10 ** page 36; example 3 *
by applicantUS5456923
 EP0901786
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.